Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long Term Safety Study of Amifampridine Phosphate in Ambulatory Patients With Spinal Muscular Atrophy (SMA) Type 3

NCT03819660 is registered in ClinicalTrials.gov with Catalyst Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03819660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03819660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long Term Safety Study of Amifampridine Phosphate in Ambulatory Patients With Spinal Muscular Atrophy (SMA) Type 3
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
March 7, 2019
Completion date
September 13, 2021
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy type 3